GlassScriptPhysician profile
Brian J Abittan
NPI 1902284482
$240,160.46
in general payments reported to CMS, 2019-2025
24 companies · $153K in 2025
The $153K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,077 · 2022: $1,278 · 2023: $42K · 2024: $42K · 2025: $153K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $219K · Food and Beverage: $8,258 · Consulting Fee: $5,509 · Travel and Lodging: $3,525 · Education: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $218,930.00 |
| Food and Beverage | $8,258.07 |
| Consulting Fee | $5,509.00 |
| Travel and Lodging | $3,524.72 |
| Education | $583.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $147,331.35 | 2022-2025 | Olumiant, Ebglyss, Taltz |
| Botanix Sb INC | $56,049.00 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $16,676.83 | 2022-2025 | Nemluvio |
| Genzyme Corporation | $6,929.37 | 2022-2025 | |
| Pfizer INC. | $4,991.58 | 2022-2025 | |
| Abbvie INC. | $1,611.55 | 2021-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,224.82 | 2021-2023 | Otezla |
| Dermavant Sciences, INC. | $1,024.58 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $998.20 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $935.60 | 2021-2024 | Tremfya |
| Merz North America, INC. | $579.32 | 2021-2023 | Xeomin |
| Arcutis Biotherapeutics, INC. | $391.67 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $348.88 | 2022-2025 | Dupixent |
| Revance Therapeutics, INC. | $240.10 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $239.38 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $146.78 | 2024-2025 | Anzupgo, Adbry |
| Journey Medical Corporation | $124.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Biofrontera INC. | $75.63 | 2024-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Sun Pharmaceutical Industries INC. | $47.32 | 2025 | |
| Ucb, INC. | $37.99 | 2023-2024 | Bimzelx |
| Mayne Pharma Commercial LLC | $26.83 | 2025 | |
| Almirall LLC | $24.95 | 2023 | Klisyri |
| Organon LLC | $5.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Abittan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.